Characterizing and overcoming chemotherapy resistance mechanisms in ovarian cancer
- Health and well-being
Google
This time the seminar is organized by FICAN South. The seminar will be held online via Microsoft Teams, and is open to everyone interested in cancer research.
Speaker: Sampsa Hautaniemi, DTech, Professor of Systems Biology
Director, Research Program in Systems Oncology (ONCOSYS) & EU Horizon
2020 consortium DECIDER.
Faculty of Medicine, University of Helsinki
Topic: Characterizing and overcoming chemotherapy resistance mechanisms in ovarian cancer
Abstract
Chemotherapy resistance is one of the greatest contributors to cancer mortality. A prime example of the impact of our current inability to overcome treatment resistance is seen in ovarian high grade serous carcinoma (HGSC), which is the most common subtype of epithelial ovarian cancer. While 90% of HGSC patients show no clinically detectable signs of cancer after surgery and chemotherapy, tumors become progressively resistant to chemotherapy leading to five-year survival of <40%.
We have established a prospective, longitudinal, multiregion observational study DECIDER (ClinicalTrials.gov identifier NCT04846933) to characterize and overcome chemotherapy resistance in HGSC. In this presentation, I will discuss our latest findings on chemotherapy resistance mechanisms in HGSC, derived from comprehensive patient-level data and ex vivo experiments. Specifically, I will focus on highlighting computational methods that facilitate high-quality data collection from patient samples, HGSC tumor evolution before and during chemotherapy, as well as translating research findings to benefit patients.
Get to know the Speaker in the web address: SYSTEM BIOLOLOGY OF DRUG RESISTANCE IN CANCER (helsinki.fi).
For further information on the seminar, please contact Outi Nikunen, email outi.nikunen@pshyvinvointialue.fi.
